United Therapeutics (NASDAQ:UTHR) EVP Sells $4,398,585.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total value of $4,398,585.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,938,901.40. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Stock Down 0.5%

Shares of UTHR opened at $524.28 on Friday. The business has a 50-day simple moving average of $490.39 and a two-hundred day simple moving average of $468.38. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The stock has a market cap of $22.98 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.89 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $6.19 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter worth about $31,000. Wilmington Savings Fund Society FSB grew its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in United Therapeutics in the 4th quarter worth about $48,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of several recent analyst reports. TD Cowen upped their price target on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group upped their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $548.09.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.